Travere Therapeutics
TVTX
165 hedge funds and large institutions have $807M invested in Travere Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 57 increasing their positions, 52 reducing their positions, and 36 closing their positions.
9.48% more ownership
Funds ownership: 109.93% → 119.41% (+9.5%)
9% more capital invested
Capital invested by funds: $737M → $807M (+$69.6M)
10% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 52
2% less funds holding
Funds holding: 169 → 165 (-4)
11% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 36
52% less call options, than puts
Call options by funds: $5.86M | Put options by funds: $12.1M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$43.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$15.2M |
| 3 |
Renaissance Technologies
New York
|
+$7.91M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$7.59M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$7.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$23.5M |
| 2 |
Millennium Management
New York
|
-$15M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$11M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$8.45M |
| 5 |
SCM
Sio Capital Management
New York
|
-$7.91M |
TVTX Hedge Fund Activity: Q4 2023 in Review
165 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2023, worth a combined $807M — up 9.4% from $737M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of TVTX and 32 opened new positions — a net loss of 4 holders — while 52 trimmed existing stakes and 57 added.
The largest buyer was Morgan Stanley, adding an estimated $43.9M. The largest seller was VR Adviser, exiting entirely with an estimated $23.5M sold.
- 165 institutional investors held Travere Therapeutics (TVTX) as of Q4 2023, down from 169 in Q3 2023.
- Funds reported $807M of Travere Therapeutics stock for Q4 2023, up 9.4% quarter-over-quarter.
- 32 funds opened new Travere Therapeutics positions in Q4 2023 and 36 closed out, a net change of -4 holders.
- The largest Travere Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $43.9M added.
- The largest Travere Therapeutics seller in Q4 2023 was VR Adviser, an estimated $23.5M sold.
Based on aggregated 13F filings for Q4 2023.